Quotient Wealth Partners LLC Purchases 153 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Quotient Wealth Partners LLC increased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 18.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 999 shares of the pharmaceutical company’s stock after purchasing an additional 153 shares during the period. Quotient Wealth Partners LLC’s holdings in Vertex Pharmaceuticals were worth $468,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of VRTX. University of Texas Texas AM Investment Managment Co. bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $25,000. Annapolis Financial Services LLC bought a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at approximately $27,000. ICA Group Wealth Management LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $28,000. Quest Partners LLC purchased a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $33,000. Finally, Founders Capital Management increased its position in shares of Vertex Pharmaceuticals by 50.0% during the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after purchasing an additional 25 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX traded up $1.35 during trading hours on Friday, hitting $481.24. 999,698 shares of the company’s stock traded hands, compared to its average volume of 1,210,800. The company has a market capitalization of $124.19 billion, a PE ratio of 31.23 and a beta of 0.39. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.52 and a quick ratio of 2.26. Vertex Pharmaceuticals Incorporated has a 52-week low of $340.83 and a 52-week high of $510.64. The firm’s 50-day moving average is $480.98 and its 200-day moving average is $444.04.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). The company had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.66 billion. Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. Vertex Pharmaceuticals’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter last year, the company earned $3.53 earnings per share. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on VRTX shares. JPMorgan Chase & Co. lifted their price objective on shares of Vertex Pharmaceuticals from $505.00 to $510.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Wells Fargo & Company upped their price target on shares of Vertex Pharmaceuticals from $540.00 to $555.00 and gave the company an “overweight” rating in a report on Monday, June 24th. Argus raised their price objective on shares of Vertex Pharmaceuticals from $465.00 to $550.00 and gave the stock a “buy” rating in a research note on Monday, June 17th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, July 26th. Finally, Redburn Atlantic started coverage on shares of Vertex Pharmaceuticals in a report on Thursday, June 27th. They set a “buy” rating and a $545.00 price objective on the stock. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $485.91.

Insiders Place Their Bets

In other news, CFO Charles F. Wagner, Jr. sold 3,250 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $454.79, for a total transaction of $1,478,067.50. Following the transaction, the chief financial officer now owns 50,387 shares of the company’s stock, valued at approximately $22,915,503.73. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CFO Charles F. Wagner, Jr. sold 3,250 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $454.79, for a total transaction of $1,478,067.50. Following the sale, the chief financial officer now owns 50,387 shares of the company’s stock, valued at approximately $22,915,503.73. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Reshma Kewalramani sold 15,202 shares of the stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $497.00, for a total value of $7,555,394.00. Following the completion of the transaction, the chief executive officer now owns 106,172 shares of the company’s stock, valued at $52,767,484. The disclosure for this sale can be found here. Insiders sold 47,065 shares of company stock valued at $22,731,946 in the last three months. 0.20% of the stock is currently owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.